AstraZeneca Results Presentation Deck
Consolidating leading position
in EGFRm lung | FLAURA2¹,²2
CEO Opening Remarks
FLAURA2 - longest mPFS >29 mo
>50% patients with CNS
metastases at baseline showed
complete response
FLAURA-2 patient with CNS LMD
showed deep, durable response
Baseline
MRI
First post-baseline Most recent follow-up
scan (6 weeks)
(25 months)
ooo
Oncology - R&D highlights
Data at WCLC and ESMO reinforce AstraZeneca leadership across tumour types
pMMR
Financial Results
dMMR
Expanding into new tumour
types in gynae | DUO-E³
First 10+ PARP inhibitor option
for 1L advanced endometrial
Deeper benefit with Lynparza in
pMMR and PD-L1+ subgroups
CTX
CTX + Imf
CTX + Imf + Lyn
CTX
CTX + Imf
CTX + Imf + Lyn
Oncology
9.7m
9.9m
7.0m
15.0m
BioPharmaceuticals
NR
31.8m
Rare Disease
Dato-DXd beat conventional
monotherapy CTX | TL01, TB014,5
PFS
Dato-DXd
vs CTX
CEO Closing Remarks
Best-in-class profile supports
combination with 10
Broad potential in earlier lines
and other tumour types
TL01
HR,
0.63
Non-squamous
2L+ NSCLC
TB01
HR,
0.63
HR+/HER2-
2L+ mBC
*Lesions in the right precentral gyrus ("motor cortex"), patient scans with permission from FLAURA2 investigator. 1. Janne PA et al. Abstract PL03.13 presented at World Conference on Lung Cancer 2023; 2. Janne PA et al. Abstract #LBA68 presented at European
Society of Medical Oncology 2023; 3. Westin S et al. Abstract #LBA41 presented at European Society of Medical Oncology 2023; 4. Ahn M et al. Abstract #LBA12 presented at European Society of Medical Oncology 2023; 5. Bardia et al. Abstract #LBA11 presented at
European Society of Medical Oncology 2023. WCLC = World Conference on Lung Cancer; ESMO = European Society of Medical Oncology; EGFRm = epidermal growth factor receptor mutation; NSCLC = non-small cell lung cancer; 1L = 1st-line; CNS = central nervous
system; CR = complete response; NEJM = New England Journal of Medicine; CTx = chemotherapy; LMD = leptomeningeal disease; MRI = magnetic resonance imaging; gynae = gynaecological; 10 = immunotherapy; PARP = poly (ADP-ribose) polymerase; p/dMRR =
17 proficient / deficient mismatch repair; PD-L1 = programmed death-ligand 1; Imf = Imfinzi; Lyn = Lynparza; NR = not reached; Dato-DXd = datopotamab deruxtecan; combo = combination; mPFS = median progression-free survival; HR = hazard ratio; 2L = 2nd-line; HR+ =
hormone-receptor positive; HER2- = human epidermal growth factor receptor 2 negative; mBC = metastatic breast cancer. Collaboration partner: Daiichi Sankyo (Dato-DXd).View entire presentation